Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study of Etanercept on a Background Non Steroidal Anti-Inflammatory Drug in the Treatment of Adult Subjects With Non Radiographic Axial Spondyloarthritis With a 92 Week Open Label Extension

Next Previous
X
Search
Trial Profile

A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study of Etanercept on a Background Non Steroidal Anti-Inflammatory Drug in the Treatment of Adult Subjects With Non Radiographic Axial Spondyloarthritis With a 92 Week Open Label Extension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary)
  • Indications Axial spondyloarthritis; Non-radiographic axial spondyloarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AS EARLY; EMBARK
  • Sponsors Pfizer

    • Most Recent Events

    • 15 Jul 2022 Results of a post hoc analysis compared the Simplified Ankylosing Spondylitis Disease Activity Score (SASDAS) against the Ankylosing Spondylitis Disease Activity Score (ASDAS) for measuring and categorizing disease activity published in The Journal of Rheumatology
    • 01 Feb 2018 Results comparing 2 years of radiographic sacroiliac joint (SIJ) changes in EMBARK and DESIR trials published in the Annals of the Rheumatic Diseases
    • 08 Nov 2017 Results assessing the impact of sustained clinical remission on MRI structural parameters in patients with early axial Spa (EMBARK; n=150 and DESIR; n=68 trials), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top